Drugs / 2-(AMINOMETHYL)PHENOL
2-(AMINOMETHYL)PHENOL
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials · 1 missed | ||||||
| Phase 2 | NCT07602166 | Jul 2026 → Jul 2031 expected | hypertensive disorder | Vanderbilt University Medical Center | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07225543 | May 2026 → Jul 2030 expected | systemic lupus erythematosus | Vanderbilt University Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT05274243 | Aug 2022 → May 2025 | rheumatoid arthritis | Vanderbilt University Medical Center | Completed | Missed primary |
| Comparator or background therapy4 trials | ||||||
| Phase 1/2 | NCT06432166 Comparator | Sep 2025 → Jun 2028 expected | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | MTI Biotech Inc | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07189936 Comparator | Dec 2025 → Jun 2028 expected | COVID-19, long COVID-19, postural orthostatic tachycardia syndrome | Vanderbilt University Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT04941599 Comparator | Feb 2024 → Jun 2026 overdue | familial hypercholesterolemia | Vanderbilt University Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT04433091 Comparator | May 2020 → Jan 2022 | atrial fibrillation | Vanderbilt University Medical Center | Completed | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 2-(AMINOMETHYL)PHENOL | ChEMBL registry synonym — accepted as the source's own label CHEMBL155572 ↗ |
| Known as | 2-(AMINOMETHYL)PHENOL ACETATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL155572 ↗ |
| Known as | 2-HOBA | “targeting IsoLGs with the IsoLG scavenger 2-hydroxybenzylamine (2-HOBA) may interrupt this immune-vascular axis, reducing salt sensitivity and associated cardiovascular risks.” NCT07602166 ↗4“2-Hydroxybenzylamine (2-HOBA), a potent small molecule scavenger of IsoLGs, sequesters the reactive species as inert adducts.” PMID 34454591 ↗ Aug 2021 “2-hydroxybenzylamine (2-HOBA), an Iso-LG-adduct scavenger” NCT07189936 ↗ |
| Known as | 2-HOBA acetate | “2-HOBA acetate (2-Hydroxybenzlamine acetate) 500mg (provided as two 250mg capsules) three times per day” NCT07225543 ↗ |
| Known as | 2-Hydroxybenzlamine acetate | “2-HOBA acetate (2-Hydroxybenzlamine acetate) 500mg (provided as two 250mg capsules) three times per day” NCT07225543 ↗ |
| Known as | 2-hydroxybenzylamine | “2-hydroxybenzylamine (2-HOBA), an Iso-LG-adduct scavenger” NCT07189936 ↗ |
| Known as | 2-hydroxybenzylamine acetate | ChEMBL registry synonym — accepted as the source's own label CHEMBL155572 ↗ |
| Known as | 2-hydroxylbenzylamine | ChEMBL registry synonym — accepted as the source's own label CHEMBL155572 ↗ |
| Known as | NSC-127870 | ChEMBL registry synonym — accepted as the source's own label CHEMBL155572 ↗ |
| Known as | Salicylamine | ChEMBL registry synonym — accepted as the source's own label CHEMBL155572 ↗ |
| Known as | Salicylamine acetate | ChEMBL registry synonym — accepted as the source's own label CHEMBL155572 ↗ |
| Modality | Small molecule | “a potent small molecule scavenger” PMID 34454591 ↗ Aug 2021 |
| Route | Oral | “2-Hydroxybenzylamine(2-HOBA) 250 mg three tabs TID (po) for seven days prior to ablation and 28 days post ablation.” NCT04433091 ↗ |